Clinical Aspects of Remaxol and Mexidol Efficiency in Complex Treatment of Primary Hypothyroidism
Research objective: to estimate efficiency of treatment with medicines Remaxol and Mexidol, in patients with the comorbid pathology of hypothyroidism assisted by dysfunction of a liver and psychosomatic frustration. Material and Methods. In the research were included 116 patients with primary hypothyroidism, assisted by disorders of functions of a liver and central nervous system. They were divided into 4 groups depending on the applied complex therapy, with studying of the main clinical symptoms of hypothyroidism, laboratory data and as well the quality of patient' life. Results. In the analysis of clinical symptoms the depression was found in 98% of cases, but after the carried-out treatment in I group it amounted to 24.32%, in II - 25.93%, in III - 25.00%. The same sign in IV group was found in 96.43% of patients, and by the end of complex treatment remained at level of 39.29%. In most cases the patient's life quality improved in the first days of therapy that could be observed by the increase of physical capacities. Studying of concentration of crude protein of plasma showed hypoproteinemia in patients taking part in the research. After the end of complex therapy the increase in crude protein concentration in I group up to 71.10 ± 0.58 g/l, in II - to 72.20 ± 1.90, in III - to 69.20 ± 0.48 and in IV - to 71.40 ± 0.53 was noted that had essential and statistically reliable differences from initial indicators (р < 0.001 for all groups). In the analysis of the data obtained after the end of treatment reliable differences of indicators of III group are revealed (to all groups p < 0.01). The maintenance of erythrocytes and hemoglobin authentically increased from initial in groups I, II and III (р < 0.005), in IV group the changes were not statistically reliable (р < 0.5). Hemoglobin level in I group increased from 116.50 ± 3.80 up to 132.36 ± 2.10 g/l, in II - from 114.26 ± 3.60 to 134.81 ± 2.00, in III -with 114.58 ± 3.50 to 127.08 ± 2.30 (р < 0.5 between groups), in IVgroup its concentration grew slightly from 115,29 ± 3,80 to 116.71 ± 2.10g/l (р < 0.5). Conclusions. Thus, use of drugs Remaxol and Mexidol for the treatment of patients with primary hypothyroidism promotes elimination of symptoms, allows increasing of clinical performance of the carried-out replacement therapy by thyroxine and at an earlier time frames to reach compensation stage and as well to stop the comorbid pathology progression. In addition, Mexidol and Remaxol have antioxidant activity and improve the function of a liver, and in particular, synthesis of proteins.